Most Read

A total of 186 patients have been enrolled into the study, surpassing the Company’s initial target of 174 patients. The increased enrolment numbers followed high engagement from study

Tessa Therapeutics (Tessa), an international clinical stage biopharmaceutical company focusing on cellular immunotherapy treatments for cancer, is a leading developer of personalized T cell therapies for solid tumors,

This marks the first approval of a long-acting treatment for opioid dependence in the EU. London’s King’s College National Addiction Centre director professor Sir John Strang, said: “Patients

The research collaboration brings together Evotec’s leading induced pluripotent stem cell (iPSC) platform and broad drug discovery capabilities with Immuneering’s unique artificial intelligence-driven drug discovery platform to accelerate

The EC’s approval is conditional on Takeda and Shire fulfilling commitments given to the EC in connection with the clearance. Specifically, in relation to the future potential overlap

LEO Pharma research vice president Thorsten Thormann said: “We are very excited about the partnership with PellePharm, who are pioneers in Gorlin Syndrome and experts in rare skin

This decision vacates the District Court’s preliminary injunction that had prohibited Dr. Reddy’s from selling its generic version of Suboxone (buprenorphine and naloxone) sublingual film. As a result

In October 2017, the FDA granted Qualified Infectious Disease Product (QIDP) and Fast Track designations for Aemcolo. With the QDIP designation, intended for antibacterial drugs that treat serious

The submission is supported by a paediatric open-label study conducted in children aged six to 11 years that investigated pharmacokinetics, pharmacodynamics and long-term safety. Mepolizumab, a humanised anti-IL5